FIRST ADDENDUM TO THE MICHIGAN STATE-SUBDIVISION AGREEMENT FOR ALLOCATION OF ALLERGAN, TEVA, CVS, AND WALMART SETTLEMENT AGREEMENTS

Addition of Walgreens Settlement

- 1. This Addendum amends the Agreement to insert Walgreens and/or the Walgreens Settlement in each appropriate location to render the Agreement equally applicable to Walgreens and the Walgreens Settlement as to the previously identified defendants and relevant settlements.
- 2. Specifically, this Addendum makes the following amendments:
 - a. Amend the title to read: Michigan State-Subdivision Agreement for the Allocation of Allergan, Teva, CVS, Walmart, and Walgreens Settlement Agreements
 - b. Amend paragraph I.V. to read: 'Settlements' are the Allergan, Teva, CVS, Walmart, and Walgreens national settlement agreements related to opioids and entered by the State between December 2022 and June 2023.
 - c. Amend the last sentence of paragraph II.9.c. to read: A Projected Attorney Fee payment from the LLGAFF may not exceed any restrictions in the Allergan, Teva, CVS, Walmart, or Walgreens Settlement Agreements, respectively, that restrict the amount of settlement funds that may be allocable to non-Opioid Remediation purposes from each of those settlements.

State of Michigan

First Addendum to the Michigan State-Subdivision Agreement for Allocation of Teva, Allergan, CVS, Walmart, and Walgreens Settlement Agreement

By: <u>Fadwa Hammoud</u>

Its: <u>Chief Deputy Attorney General</u>